| Outcome Measures: |
Primary: Metabolic Clearance Rate of Insulin, The change from baseline in calculated metabolic clearance rate of insulin as measured by the 2-step Hyperinsulinemic-Euglycemic Clamp., 12-Weeks|Rate of Resting Energy Expenditure (REE), Change from baseline REE as measured by indirect calorimetry., 12-Weeks|Change in Beta-hydroxybutyrate (BHB) Level, The change from baseline in peak BHB production as measured by the insulin withdrawal challenge., 12-Weeks|Change in Free Fatty Acid (FFA) Level, The change from baseline in peak FFA production as measured by the insulin withdrawal challenge., 12-Weeks|Change in mRNA Expression, The change from baseline in gene mRNA expression as measured by adipose and muscle tissue samples., 12-Weeks|Change in Peripheral Macrovascular Vasodilation, The change from baseline in post-stimulus vessel diameter as measured by flow mediated dilation., 12-Weeks|Change in Peripheral Microvascular Vasodilation, The change from baseline in reactive hyperemia index as measured by reactive hyperemia-peripheral arterial tonometry (RH-PAT)., 12-Weeks|Change in Cardiovascular Disease (CVD) Risk Markers., The change in pg/mL from baseline in CVD risk markers (SAA, CRP, VCAM-1 and ICAM-1) as measure by blood samples., 12-Weeks|Change in Cardiovascular Disease (CVD) Risk Markers., The change in ng/mL from baseline in CVD risk markers (Thrombomodulin, ICAM-3, E-Selectin and P-Selectin) as measure by blood samples., 12-Weeks |
|
